J&J Q2 2026: Sales Beat and Raised Guidance, but STELARA Erosion and Talc Overhang Linger
JNJ sits 58% above its 52-week low of $164.23.
Summary
Strong Q2 2026 results beat estimates and prompted a full-year guidance raise, but STELARA sales plunged 55% under biosimilar pressure. The filing also revealed a $1B acquisition, a new credit facility, and restructuring costs, while the talc reserve holds at $3.7B.
Key Events · Earnings and Guidance · JNJ
-
Q2 2026 Earnings Beat
Sales of $25.31B (+6.6% YoY) and adjusted EPS of $2.90 exceeded consensus. Net earnings were $5.53B, with diluted EPS of $2.27.
-
Full-Year Guidance Raised
The 2026 outlook was lifted: reported sales are now seen at $100.8B–$101.8B (up from prior) and adjusted EPS at $10.50–$10.70.
-
STELARA Sales Collapse
Biosimilar competition drove STELARA revenue down 55.2% in Q2 to $740M. The decline is expected to continue, with SIMPONI biosimilars entering Europe in Q2 2026.
-
Talc Litigation Reserve at $3.7B
The total present value of the talc reserve is $3.7B, with 40% classified as current. Approximately 76,000 plaintiffs have direct claims pending.
Analysis · JNJ · Life Sciences
A clean Q2 beat—sales of $25.31B and adjusted EPS of $2.90, both above consensus—allowed Johnson & Johnson to lift its full-year 2026 guidance. The company now sees reported sales of $100.8B–$101.8B and adjusted EPS of $10.50–$10.70. Yet the quarter also laid bare the accelerating decline of STELARA, down 55.2% as biosimilar competition bites, while the talc litigation reserve stands at $3.7B. Elsewhere in the filing, a new $1B acquisition of Firefly Bio, a $12.5B credit facility, and a supply chain restructuring were disclosed. The stock trades near its 52-week high, buoyed by launches such as TREMFYA and the recent FDA authorization of the OTTAVA surgical robot, though the talc overhang and biosimilar headwinds remain key risks.
At the time of this filing, JNJ was trading at $259.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $624.1B. The 52-week trading range was $164.23 to $269.43. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.